Urge Congress to Fund Sickle Cell Research & Awareness
As we recover from the pandemic, investments in research and education that address health disparities in underserved communities are more critical than ever. Congresswoman Barbara Lee (D-CA) is leading Congressional efforts to increase awareness and funding for sickle cell disease and sickle cell trait, which disproportionally impacts Black and Latino communities. Ask Congress to support sickle cell research and help ensure access to testing and lifesaving information. Send an email in support by clicking on the Source button below.
Take action and join UCSF and SCAASF in asking Congress to support sickle cell research and help ensure access to testing and lifesaving information. Your advocacy is timely as September honors Sickle Cell Awareness Month. Submit your email in support using this customizable template from the Source button below, and find other ways to get involved and support the sickle cell community at tiny.ucsf.edu/sicklecell.
Sickle cell disease is the most common inherited blood disorder in the U.S. At least 3 million people in the U.S. carry the sickle cell trait that can lead to adverse health complications, including 1 in 12 African Americans and 1 in 100 Latinos. Early diagnosis and treatment can slow or prevent some medical complications. Unfortunately, many people don’t know their status. We must ensure everyone has the tools, support, and treatment options needed to prevent and fight sickle cell disease. Ask your Congressmember to support funding for sickle cell research and prevention today (H.Res.494 and H.Res.495).
You can get involved at the local level by joining the Sickle Cell Anemia Awareness of San Francisco 8th Annual KMJ Sickle Cell Warrior Walk on September 11 at the Bayview Opera House.
About UCSF Sickle Cell Research & Patient Care
UCSF Benioff Children’s Hospital in Oakland's Comprehensive Center for Sickle Cell Disease is the largest and most comprehensive program for sickle cell disease in the Western US. Legislation like H.Res.494 and H.Res.495 will enable UCSF to expand research and work with partners to find a cure.
In collaboration with UC Berkley and UC Los Angeles, UCSF recently launched an early phase, first-in-human trial of CRISPR gene correction therapy for patients with sickle disease using their own blood-forming stem cells for treatment. By focusing on innovative research and offering the latest treatments, UCSF helps sickle cell patients to achieve the best quality of life possible. Read more here.